Growing numbers of studies have pushed this field of study into clinal trials with promising results, as was seen with the gastric cancer umbrella study and in subsets of larger precision oncology clinical trials (O’Dwyer et al., 2023; Rodon et al., 2019) not only showing whether a particular clinical trial for a therapy is effective but by virtue of testing increasing knowledge of molecular significance of tumors; HER2 amplification for instance was found at a frequency of 2% in multiple tumors, not including breast cancers and gastric cancers (Jhaveri et al., 2019). This evidence concerns the gene ERBB2 and breast carcinoma.